bioMérieux ConnectionAn educational resource brought to you by bioMérieux, Inc.
An educational resource brought to you by bioMérieux, Inc.
The cornerstone of Cayuga Medical Center’s investment was the acquisition of a microbial identification technology using mass spectrometry, called MALDI-TOF mass spec. But Cayuga didn’t stop there.
By the bioMérieux Connection Editors In late 2013, the U.S. Food and Drug Administration (FDA) granted 510(k) de novo clearance to the first mass spectrometer for identifying disease-causing bacteria and yeast for clinical use in the U.S. market. The technology is called Matrix-Assisted Laser Desorption Ionization-Time of Flight mass spectrometry, or MALDI-TOF MS, and it uses a …
At this year’s World Anti-Microbial Resistance Congress, Dr. Tristan Timbrook delivered a...
WASH, which stands for water, sanitation, and hygiene, are basic...